title: Evaluation of a soybean product fujiflavone P40 as an antiosteoporotic agent in rats.
abstract: The preventive effects of Fujiflavone P40 (a soybean isoflavone product) against both bone loss and periodontal alteration were evaluated using an ovariectomized rat model. Rats were divided into five groups: sham-operated (Sham), ovariectomized (OVX), OVX given Fujiflavone P40, OVX given 17beta-oestradiol, and OVX given the vehicle for 17beta-oestradiol, respectively. Fujiflavone P40 contains 46.6% isoflavones which consist of 24.1% daidzin, 16.5% glycitin and 5.9% genistin. Administration of Fujiflavone P40 to OVX rats suppressed the body weight gain until 5 weeks. Fujiflavone P40 also decreased total and high-density lipoprotein (HDL) cholesterols and triglyceride level of OVX rats, significantly. After 7 weeks, Fujiflavone P40 did not recover the coarsened fibre of the periodontal ligament. The ovariectomy decreased the uterine weight by 78%. The administration of 17beta -oestradiol recovered the weight loss by 99%, while Fujiflavone P40 restored it by 33%. The ovariectomy decreased the tibial bone mineral density (BMD) by 22%. The administration of 17beta-oestradiol to OVX rats recovered the tibial BMD decrease by 100%, while Fujiflavone P40 recovered it by 78%. The results suggest that Fujiflavone P40 may be useful as a preventive agent for osteoporosis.
authors.affiliation: Department of Dental Hygiene, Fukuoka College of Health Sciences, Fukuoka, Japan. sabrnrn@college.fdcnet.ac.jp
authors.forename: Saburo
authors.initials: S
authors.lastname: Hidaka
authors.forename: Yoshizo
authors.initials: Y
authors.lastname: Okamoto
authors.forename: Koji
authors.initials: K
authors.lastname: Miyazaki
authors.forename: Takehiko
authors.initials: T
authors.lastname: Uesugi
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D008076:Cholesterol, HDL / Q000187:drug effects; D004195:Disease Models, Animal; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D007529:Isoflavones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008334:Mandible / Q000187:drug effects / Q000648:ultrastructure; D008855:Microscopy, Electron, Scanning; D010024:Osteoporosis / Q000188:drug therapy*; D010052:Ovariectomy; D010513:Periodontal Ligament / Q000187:drug effects / Q000648:ultrastructure; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013025:Glycine max; D013977:Tibia / Q000187:drug effects / Q000648:ultrastructure; D014280:Triglycerides / Q000378:metabolism
chemical_list: D008076:Cholesterol, HDL; D007529:Isoflavones; D010936:Plant Extracts; D014280:Triglycerides; C473894:fujiflavone P40; D004958:Estradiol; D002784:Cholesterol